Online inquiry

IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1606MR)

This product GTTS-WQ1606MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets GDF11 gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005811.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10220
UniProt ID O95390
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ1606MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11332MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-524
GTTS-WQ11453MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ14848MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ2935MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ5041MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ3109MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA APN311
GTTS-WQ11883MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ15144MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SYNT-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW